This post was originally published on this site

[unable to retrieve full-text content]Seagen Inc. SGEN along with Japanese partner Astellas Pharma, Inc announced positive top-line data from the second cohort of the pivotal phase II EV-201 study, which is evaluating their antibody-drug …